The drug major on Wednesday announced that Lupin Diagnostics has launched its first regional reference laboratory in Patna, Bihar.
Lupin Diagnostics offers a comprehensive range of diagnostics services to doctors, patients and consumers. The new regional reference laboratory at Patna has capabilities to conduct a broad spectrum of routine and specialized tests in the fields of molecular diagnostics, cytology, microbiology, serology, haematology, immunology and routine biochemistry.
The company said that by establishing a presence in Patna, the company now looks forward to making a deeper foray into Bihar. Earlier this year, Lupin Diagnostics opened its regional reference laboratories in Assam and West Bengal. Through upcoming launches of laboratories in Jharkhand (Ranchi) and Orissa (Bhubaneshwar), the company is poised to solidify its position in East India.
Lupin Diagnostics now operates through more than 100 diagnostic centers in East India and close to 280 centers across the country.
Ravindra Kumar, vice president and head of Lupin Diagnostics said: "We are pleased to announce the launch of our regional reference laboratory in Patna. Through this we plan to provide quality and affordable testing services for a broad range of routine and specialized tests across the state of Bihar. By leveraging our extensive network of LupiMitra centers, we will make quality diagnostics services available to patients even in the most remote areas."
Lupin is a transnational pharmaceutical company. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The pharma giant reported a consolidated net loss of Rs 518 crore in Q4 FY22 as against a net profit of Rs 460.4 crore in Q4 FY21. Income from operations rose by 2.8% year on year to Rs 3,864.5 crore during the quarter.
Shares of Lupin were up 0.97% at Rs 614.65 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app